Read as much as you want on BostonGlobe.com, anywhere and anytime, for just 99¢.

Amgen settles US cases for $762m

Amgen Inc. has agreed to pay $762 million to resolve federal litigation accusing the drug maker of marketing the anemia treatment Aranesp for unapproved uses.

The company pleaded guilty Tuesday to illegally introducing a misbranded drug into interstate commerce and will pay a $136 million fine and a $14 million forfeiture, according to the US Attorney’s Office for the Eastern District of New York.

Continue reading below

It also agreed to a $612 million civil settlement according to a law firm connected to the case.

But the US attorney’s office declined to comment on that because the civil settlement won’t be unsealed until a Wednesday court hearing.

Amgen said in an e-mail that if the court accepts the plea and sentence, it will immediately resolve civil and criminal matters.

Loading comments...

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week